The present work investigates protein tyrosine phosphatase 1B (PTP1B) and the α-glucosidase inhibitory activities of two edible brown algae, Ecklonia stolonifera and Eisenia bicyclis, as well as in their isolated phlorotannins. Since the individual extracts and fractions showed significant inhibitory activities, column chromatography was performed to isolate six phlorotannins, phloroglucinol (1), dioxinodehydroeckol (2), eckol (3), phlorofurofucoeckol-A (4), dieckol (5), and 7-phloroeckol (6). Phlorotannins 3–6 were potent and noncompetitive PTP1B inhibitors with IC50 values ranging from 0.56 to 2.64 μM; 4–6 exhibited the most potent α-glucosidase inhibition with IC50 values ranging from 1.37 to 6.13 μM. Interestingly, 4 and 6 were noncompetitive, while 5 exhibited competitive inhibition in an α-glucosidase assay. E. stolonifera and E. bicyclis as well as their isolated phlorotannins therefore possessed marked PTP1B and α-glucosidase inhibitory activities; this could lead to opportunities in the developme...
Along with diabetes and obesity, chronic kidney disease (CKD) is increasing across the globe. Although some data support an effect of maternal obesity on offspring kidney, the impact of paternal obesity is unknown; thus, we have studied the effect of paternal obesity prior to conception. Male Sprague Dawley rats were fed chow diet or high fat diet (HFD) for 13–14 weeks before mating with chow-fed females. Male offspring were weaned onto chow and killed at 27 weeks for renal gene expression and histology. Fathers on HFD were 30% heavier than Controls at mating. At 27 weeks of age offspring of obese fathers weighed 10% less; kidney triglyceride content was significantly increased (5.35 ± 0.84 vs. 2.99 ± 0.47 μg/mg, p < 0.05, n = 8 litters per group. Histological analysis of the kidney demonstrated signs of tubule damage, with significantly greater loss of brush border, and increased cell sloughing in offspring of obese compared to Control fathers. Acat1, involved in entry of fatty acid for beta-oxidation, was significantly upregulated, possibly to counteract increased triglyceride storage. However other genes involved in lipid metabolism, inflammation and kidney injury showed no changes. Paternal obesity was associated with renal triglyceride accumulation and histological changes in tubules, suggesting a mild renal insult in offspring, who may be at risk of developing CKD.
Maternal obesity impacts offspring metabolism. We sought to boost mitochondrial energy metabolism using the nicotinamide adenine dinucleotide (NAD+) precursor nicotinamide mononucleotide (NMN) to treat metabolic impairment induced by maternal and long-term post weaning over-nutrition. Male offspring of lean or obese mothers, fed chow or high fat diet (HFD) for 30 weeks post-weaning, were given NMN injection, starting at 31 weeks of age, daily for 3 weeks before sacrifice. Glucose tolerance was tested at 10, 29 and 32 weeks of age to measure short and long term effects of post-weaning HFD, and NMN treatment. Plasma insulin and triglycerides, liver triglycerides and expression of mitochondrial metabolism-related genes were measured at 34 weeks. Impaired glucose tolerance due to maternal and post weaning HFD was significantly improved by only 8 days of NMN treatment. Furthermore, in offspring of obese mothers hepatic lipid accumulation was reduced due to NMN treatment by 50% and 23% in chow and HFD fed offspring respectively. Hepatic genes involved in fat synthesis, transport and uptake were reduced, while those involved in fatty acid oxidation were increased by NMN. Overall this finding suggests short term administration of NMN could be a therapeutic approach for treating metabolic disease due to maternal and post weaning over-nutrition, even in late adulthood.
In an attempt to develop alternative medicine for the treatment of diabetes and related complications, the antidiabetic potential of the fruits of Crataegus pinnatifida was evaluated. The antidiabetic potential of the methanol (MeOH) extract as well as different solvent soluble fractions of the fruits of C. pinnatifida was evaluated via α-glucosidase, protein tyrosine phosphatase 1B (PTP1B), rat lens aldose reductase (RLAR), and advanced glycation end products (AGEs) formation inhibitory assays. The MeOH extract showed potent inhibitory activity against α-glucosidase, PTP1B, and AGEs formation with IC50 values of 122.11, 3.66 and 65.83 μg/ml respectively, while it showed moderate inhibitory activity against RLAR with the IC50 value of 160.54 μg/ml. Among different fractions, the ethyl acetate (EtOAc) and the dichloromethane (CH2Cl2) fractions were found as active fractions exhibiting potential α-glucosidase, PTP1B, RLAR inhibitory, and AGEs formation inhibitory activities. Seven compounds including hyperoside, chlorogenic acid, ursolic acid, oleanolic acid, 3-epicorosolic acid, β-sitosterol, β-sitosterol glucoside were isolated from these two fractions. 3-Epicorosolic acid showed both potent α-glucosidase and PTP1B inhibitory activities with IC50 values of 30.18 and 4.08 μg/ml respectively. Moreover, kinetic study revealed that 3-epicorosolic acid showed mixed type inhibition against PTP1B, while it showed uncompetitive inhibition against α-glucosidase. Therefore, these results suggest that the fruits of C. pinnatifida and its constituents have potential antidiabetic activity which might be used as a functional food for the treatment of diabetes and associated complications.
We reported that allogeneic “Neo-Islets” (NIs), organoids composed of ~ equal numbers of Mesenchymal Stromal Cells and culture expanded Islet Cells (ICs) do, when given i.p., omentally engraft and permanently restore euglycemia in auto-immune diabetic NOD mice, i.e., without the use of either encapsulation devices or antirejection drugs. Similarly, spontaneously diabetic pet dogs treated with allogeneic canine NIs (cNIs) significantly improve glycemia with ~ 50% reduction in insulin needs (> 2 years), and this without immune response. In preparation for a Phase I Clinical Trial we tested whether human ICs in NIs (hNIs) are biologically comparable to canine Islet Cells (cICs) and cNIs, i.e., cells from a larger diabetes model. In our preclinical mouse and dog studies, insulin and other islet hormone gene expression levels were used as indicators of ICs in NIs to adequately re-differentiate into insulin and islet-specific endocrine cells when implanted i.p., thereby resulting in physiological control of T1DM.Human islet cells from 6 donors of different demographics were cultured, passaged to P4, and their growth rates, insulin and other islet-associated endocrine genes’ expression levels, secretion of insulin in response to glucose stimulation (GSIS), and NI formation abilities were compared. Results: (1) hICs and hNIs show comparable gene expression profiles to those of cICs and cNIs, and hNIs show identical GSIS responses to those of cNIs. (2) Insulin gene expression profiles of hICs are stable as a function of population doublings and independent of donor diversity. In conclusion, these data indicate that donor variability does not appear to be a significant factor in this NI technology, facilitating our IND work and further demonstrating hNIs’ translational potential in a planned Clinical Trial in subjects with T1DM. Disclosure: A. Gooch: Employee; Self; SymbioCellTech. S.S. Chowdhury: Employee; Self; SymbioCellTech. P. Zhang: Employee; Self; SymbioCellTech. Z. Hu: Employee; Self; SymbioCellTech. C. Westenfelder: Consultant; Self; SymbioCellTech.
We demonstrated that ip administration of “Neo-Islets” (NIs; co-aggregation of allogeneic, culture-expanded Islet cells (ICs) with Adipose derived Stem Cells (ASCs)), resulted in their omental engraftment in immune-competent, diabetic NOD mice. This achieved durable euglyciemia without immunosuppression, and with physiologic delivery of insulin and other islet hormones (SCTM 2017;6:1631). We are conducting an FDA guided pilot study (INAD 012-1248) of this technology in spontaneously T1DM pet dogs (see abstract this session). ICs and ASCs are known to be subject to gluco- and lipotoxicity. We undertook this study to determine whether the Hypertriglyceridemic (HTG) and/or DM milieu has an adverse effect (lipotoxic and/or glucotoxic) on dog ASCs and ICs and NIs. Accordingly, serum was collected from HTG, DM dogs enrolled in INAD 012-776 before and after control of HTG and glucose levels, and from non-DM HTG dogs. These sera were added separately (10%) to DMEM at either 5mM or 17mM glucose for dog ASC and IC cultures. Growth rates and gene expression profiles were assessed. Serum from DM (glucose 123-742 mg/dL) dogs with untreated HTG (range 656-1248 mg/dL; normal 20-248 mg/dL) killed ICs at either 5 or 17 mM glucose, and failed to support the expansion of ASCs in 17mM glucose. For ASCs grown in 17mM glucose expression of IL-6 and IGF-1 were downregulated. In contrast, sera from DM dogs with controlled HTG (range 146-656 mg/dL), and serum from HTG (range 742-1114 mg/dL), non-DM dogs supported the growth of both cell types in either medium with no changes in gene expression. In agreement with these in vitro results, an uncontrolled NI-treated study dog failed to respond to therapy, while HTG and glucose-controlled dogs have shown up to 50% reduced need for insulin 12 months post therapy. Conclusion: These data demonstrate the need for optimal glucose and lipid control to prevent destruction of the NI cells when treating DM. Disclosure: A. Gooch: Board Member; Self; SymbioCellTech. S.S. Chowdhury: Employee; Self; SymbioCellTech. C. Westenfelder: Consultant; Self; SymbioCellTech.